HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

N- (4,6- dimethylpyrimidin- 2- yl)- 4- (2- (4- methoxy- 3- methylphenyl)- 5- (4- methylpiperazin- 1- yl)- 4,5,6,7- tetrahydro- 1H- indol- 1- yl)benzenesulfonamide difumarate

structure in first source

Also Known As:

YM-393059

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - N-(4,6-dimethylpyrimidin-2-yl)-4-(2-(4-methoxy-3-methylphenyl)-5-(4-methylpiperazin-1-yl)-4,5,6,7-tetrahydro-1H-indol-1-yl)benzenesulfonamide difumarate: 3

Experts

1.	Ikeda, Ken: 3 articles (03/2007 - 07/2006)
2.	Shimizu, Yasuaki: 3 articles (03/2007 - 07/2006)
3.	Sugahara, Shingo: 3 articles (03/2007 - 07/2006)
4.	Yamamoto, Satoshi: 3 articles (03/2007 - 07/2006)
5.	Ichikawa, Atsushi: 1 article (07/2006)
6.	Naito, Ryo: 1 article (07/2006)
7.	Yamada, Toshimitsu: 1 article (07/2006)

Related Diseases

1.	Rheumatoid Arthritis 03/22/2007 - "In this study, we investigated the therapeutic potential of YM-393059 for the treatment of rheumatoid arthritis in several animal models. " 03/22/2007 - "These results suggest that YM-393059 is an attractive compound for the treatment of autoimmune disorders such as rheumatoid arthritis."
2.	Vomiting 07/10/2006 - "In contrast to YM976, YM-393059 did not shorten the duration of alpha2-adrenoceptor agonist-induced sleep in mice, which is a model for the assessment of the typical side effects caused by PDE4 inhibitors, nausea and emesis. "
3.	Nausea 07/10/2006 - "In contrast to YM976, YM-393059 did not shorten the duration of alpha2-adrenoceptor agonist-induced sleep in mice, which is a model for the assessment of the typical side effects caused by PDE4 inhibitors, nausea and emesis. "
4.	Inflammation (Inflammations) 11/21/2006 - "To characterize the pharmacological profile of YM-393059, its effects on several acute and chronic inflammation models were examined. " 11/21/2006 - "Pharmacological profile of a novel phosphodiesterase 7A and -4 dual inhibitor, YM-393059, on acute and chronic inflammation models." 11/21/2006 - "In acute inflammation models, YM-393059 significantly suppressed the delayed-type hypersensitivity reaction to sheep red blood cells in mice with an ED(50) value of 17.1 mg/kg. YM-393059 failed to suppress paw edema in the carrageenin-induced edema model in rats. " 11/21/2006 - "However, YM-393059, but not cyclosporine, significantly inhibited zymosan-induced neutrophil accumulation in mice with an ED(50) value of 25.7 mg/kg. In mouse toluene-2,4-diisocyanate-induced contact dermatitis, a chronic inflammation model, YM-393059 and cyclosporine significantly suppressed ear edema at doses of 30 and 20 mg/kg, respectively. "
5.	Hypersensitivity (Allergy) 11/21/2006 - "In acute inflammation models, YM-393059 significantly suppressed the delayed-type hypersensitivity reaction to sheep red blood cells in mice with an ED(50) value of 17.1 mg/kg. YM-393059 failed to suppress paw edema in the carrageenin-induced edema model in rats. "

Related Drugs and Biologics

1.	Cyclosporine (Ciclosporin)
2.	Phosphodiesterase 4 Inhibitors
3.	Type 7 Cyclic Nucleotide Phosphodiesterases
4.	Zymosan
5.	Phosphoric Diester Hydrolases (Phosphodiesterases)
6.	Carrageenan
7.	YM 976